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RVR, SVR12 and SVR24 than placebo. There was no difference in the safety of sofos-
buvir and placebo groups for the majority of evaluated outcomes. ConClusions: 
Our meta-analysis indicates promising efficacy and a good safety profile of sime-
previr for both evaluated doses. Data concerning sofosbuvir reveal the benefits of 
this drug in hepatitis C virus genotype 1 treatment, also in safety terms.
PIN4
AssocIAted FActors the VIrologIc success IN A grouP oF PAtIeNts 
WIth humAN ImmuNodeFIcIeNcy VIrus, mANAged By A cAre teAm 
INtegrAl, ePs|surA medellIN 2010-2013
Estrada JI1, Restrepo AM1, Serna JA2, Abad JM1, Segura AM3
1CES University, Medellin, Colombia, 2UPB University, Medellin, Colombia, 3Antioquia University, 
Medellin, Colombia
introduCtion: the probability of occurrence of virological failure in patients 
diagnosed with HIV in ARV drug treatment of first and second line is 0.15 and 0.46 
respectively, produce the emergence of viral resistance, loss of future schemes, 
increased hospital admissions, disease progression and death. objeCtives: To 
determine the associated factors that explain the virological success and the time 
needed to reach it. Methods: Type of study: retrospective cohort survival analysis. 
Type of patients: belonging to EPS|SURA regional Medellin, diagnosed with HIV and 
exposed to first time antiretroviral therapy. Variables: dependents (virologic suc-
cess and time required to reach it) and independents (sociodemographic, clinical 
and pharmacotherapeutic). Analysis:frequencies, summary measures, and Kaplan 
Meier for the univariate stage, chi square, Student’s t test or Mann-Whitney U 
and Log Rank Test for the bivariate phase, proportional hazards model and mul-
tiple logistic regression in multivariate phase. results: 97% of patients achieved 
virologic success, needed 209 days (SD±10.14). Patients had a 95% probability of 
achieving virological success in the first 8.5 months. Properly use drugs was asso-
ciated with a shorter time to achieve virologic success HR 2.68 [1.22-5.90] and a 
greater number of problems with drugs was associated with a longer time HR 0.60 
[0.43-0.83]. ConClusions: virological success was higher than the studies found, 
which was obtained in a short time and was maintained throughout the observation 
period. The variables in this study were not associated with virologic success but 
were associated with a shorter time to reach it.
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objeCtivos: Estudiar la evolución del consumo de antibacterianos de uso restrin-
gido en pacientes adultos hospitalizados durante el periodo 2005 al 2012, en el 
hospital Las Higueras de Talcahuano. MetodologíAs: Se realizó un estudio ret-
rospectivo durante los años 2005 - 2012, del consumo mensual de antibacterianos 
de uso restringido. Los antibacterianos considerados fueron clasificados según el 
sistema ATC/DDD. Se incluyo vancomicina, carbapenémicos (imipenem, ertapenem 
y meropenem) y cefalosporinas de tercera generación (ceftriaxona, ceftazidima y 
cefotaxima). Se determinó la densidad de consumo expresado en porcentaje y en 
términos del número de DDD/100 días-cama-ocupados. La evolución del consumo 
se determinó calculando diferencia porcentual entre los año 2005 y 2012. La com-
paración de los consumos se realizó con la prueba t-test. Se consideró diferencias 
significativas con un nivel de significancia de p< 0.05. resultAdos: Ceftriaxona 
fue el antibacteriano con mayor consumo total (63%) (292,4 DDD/100 días-cama-
ocupados) seguido por vancomicina (17%) (77,13 DDD/100 días-cama-ocupados). 
Por su parte, el servicio de paciente crítico y de cirugía mostraron el mayor con-
sumo de antibióticos, con un total de 150 DDD/100 días-cama-ocupados (54%) y 54 
DDD/100 días-cama-ocupados (20%) respectivamente. En relación a la evolución del 
consumo, se observó un incremento significativo en el consumo de vancomicina 
(+67%; p< 0,05), imipenem (+62%; p= 0.004), meropenem (+84%; p= 0.006) y ceftri-
axona (+44%; p= < 0.05). ConClusiones: El consumo de todos los antibióticos 
estudiados aumento significativamente, especialmente ceftriaxona, vancomicina 
y carbapenémicos. La consecuencia de este consumo pudiera significar un aumento 
de la resistencia bacteriana intrahospitalaria y los costos asociados en la atención 
de salud, por lo que se sugiere su estudio.
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bACkground: It is World Health Organization’s Global Plan to eradicate Tuberculosis 
(TB) disease by the year of 2050, but it is difficult to achieve that goal by the current 
rate of infection decrease. Our goal is to evaluate whether calcium channel blocker, 
an existing cardiovascular drug can affect the onset of active TB. objeCtives: To 
evaluate whether the use of different classes of calcium channel blockers (CCBs) affect 
the risk of incident active tuberculosis disease. Methods: A nested case control 
study was carried out using the claims data from National Health Insurance Research 
Database of Taiwan between January 1997 and December 2011. Index date referred to 
the first date of TB diagnosis. Patients with CCBs exposure were defined by receiving ≧ 
7 days of prescription ending in 3 different time frames. Current use refers to prescrip-
tion that ended within 30 days of the index date. Multivariate regression and a disease 
risk score (DRS) technique were used to calculate risk of active TB disease. results: 
INFectIoN – clinical outcomes studies
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objeCtives: To assess malaria diagnosis and treatment practices follow-
ing introduction of rapid diagnostic test in Adama district health posts, central 
Ethiopia. Methods: A Cross-sectional study was conducted from January 24 to 
February 9, 2014 among febrile patients, and caretaking health workers to determine 
the perceptions and practices related to rapid diagnostic tests (RDTs). Moreover, the 
treatments prescribed were assessed at the selected Health posts. From the total of 
37 health posts in Adama district, 10 health posts were selected by simple random 
sampling technique. All the patients who visited the health posts during the study 
period and all health service providers working in the selected health posts were 
included in the study. results: The survey was undertaken at ten health posts 
which use RDT for parasitological confirmation. Twenty health workers and 104 
patients were interviewed at health posts. Eighty three patients (79.8%) were seen in 
health posts with available parasite based diagnostic test (i.e. RDT)) and 21(20.2%) in 
facilities without RDT. The overall malaria positivity rate was 48(57.8%). Anti–malaria 
drugs were prescribed to all 48(100%) patients with positive RDT and to 19(54.3%) of 
RDT negative patients. Among non-tested patients, anti-malaria drugs were given 
to 12(57.1%), with a higher prescription rate in health posts without RDTs results. 
Among 104 patients presenting with fever or history of fever, 64(61.5%) were pre-
scribed with antibiotics and anti-pain. ConClusions: Findings from this study 
show that over prescription with anti-malarial drugs is common in Adama district 
health posts. The use of rapid malaria diagnostics was also associated with higher 
prescription of antibiotics among patients with negative test results. The Adama 
district health office should provide on job and other capacity building trainings for 
health workers on RDTs, the diagnosis and management of other causes of fever 
and the importance of adhering to test results.
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objeCtives: To assess the effect of human leukocyte transfer factor for paren-
teral use (TF) in adult and pediatric patients suffering from cellular immunode-
ficiency (CID) in whom TF had been indicated for treatment of respiratory and/
or urinary tract infections, prostatitis and/or vulvovaginitis episodes. Methods: 
Observational multicenter retrospective study in subjects being treated with TF in 
the period from September 2012 to April 2013 in Slovakia. The primary objective 
was to evaluate the effectiveness by assessment of the number of documented 
infections over one year since the treatment began as compared to the last year 
of the pre-treatment period. Moreover, the resource use and QoL assessment was 
conducted using EQ-5D. results: The sample (98 analyzed patients) in 9 centers 
was predominantly female (75.5%) and the average age was 46.6, with a range of 
7 to 82. The most common recurrent episodes were respiratory tract infections 
occurring 5 (472/96 with infection) times at average in the year before TF initia-
tion (96 patients), followed by urinary tract infections (n= 38) and vulvovaginitis 
episodes. The significant reduction was observed in all three types of recurrent 
infections after treatment with TF (prostatitis not analyzed). Respiratory tract infec-
tions where reduced from 5 to 2 a year after, in contrast to the period before initia-
tion of TF application (p< 0.001). Significant reduction was achieved in urinary tract 
infections and vulvovaginitis episodes (p< 0.001). Reduction was accompanied by a 
lower resource use, measured by the need of antibiotics and hospitalizations. The 
median of parenteral TF doses was 8 injections for a full study period (maximum 
2 years). ConClusions: The conducted study showed that leukocyte human TF 
helps to reduce recurrence of episodes of infections in adult and pediatric patient 
with CID. Besides clinical and resource outcomes, the contribution of this study is 
the elicitation of utility values for CID of different severity.
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objeCtives: To evaluate the efficacy and safety of the second-wave direct-act-
ing antivirals simeprevir and sofosbuvir in patients with HCV genotype 1 infec-
tion through a systematic review and meta-analysis of randomized clinical trials 
(RCTs). Methods: Electronic searches were performed in databases MEDLINE, 
International Pharmaceutical Abstracts (IPA), Cochrane Library, SCIELO and Scopus. 
Statistical analyses were executed using the software Review Manager version 
5.3. results: 774 articles were identified, of which 10 RCTs were selected for data 
extraction and statistical analysis. Simeprevir 100 mg promoted better RVR and 
SVR24 Resultsthan placebo, and simeprevir 150 mg was superior to placebo for the 
following outcomes: RVR, SVR12, SVR24, SVR12 rates according to METAVIR score 
for the subgroups F0-F2, F3 and F4, SVR12 rates according to HCV genotype for both 
genotype 1a and genotype 1b, SVR12 rates for HCV genotype 1a without baseline 
Q80K and SVR12 according to IL28B genotype for CC, CT and TT. More viral relapse 
events were observed in the placebo group, for both evaluated doses. There were no 
significant differences for all of the evaluated safety outcomes between the sime-
previr 100 mg and the placebo groups, and for almost all evaluated safety outcomes 
between the simeprevir 150 mg and placebo groups. Sofosbuvir promoted better 
